Within the field of allogeneic chimeric antigen receptor T-cell therapy, La Jolla, CA–based Fate Therapeutics is exploring in vitro differentiation of induced pluripotent stem cells, rather than T cells harvested from donors, as their source material. Preclinical data on the company's off-the-shelf candidate, FT819, look promising so far.
https://ift.tt/2J42EA9
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου